Key regions: France, Europe, United Kingdom, Brazil, India
The demand for oncology drugs in the Commonwealth of Independent States (CIS) has been on the rise in recent years, driven by several factors that have contributed to the growth of the market.
Customer preferences: Patients in CIS countries are increasingly seeking out innovative treatments that can improve their quality of life and increase their chances of survival. As a result, there has been a growing demand for targeted therapies and immunotherapies, which have shown promising results in treating various types of cancer.
Trends in the market: One of the key trends in the CIS oncology drugs market is the increasing availability of innovative treatments. Pharmaceutical companies are investing heavily in research and development to bring new drugs to market, and many of these drugs are now becoming available in CIS countries. In addition, there has been a growing trend towards personalized medicine, with treatments being tailored to the specific needs of individual patients.
Local special circumstances: However, the CIS oncology drugs market also faces some unique challenges. One of the biggest challenges is the lack of access to healthcare in many parts of the region. This has resulted in a significant proportion of the population being unable to access the latest treatments, particularly in rural areas. In addition, there are significant disparities in healthcare provision between different countries in the region.
Underlying macroeconomic factors: The growth of the CIS oncology drugs market is being driven by a range of underlying macroeconomic factors. These include the increasing prevalence of cancer in the region, as well as rising levels of disposable income and improvements in healthcare infrastructure. In addition, there has been a growing focus on healthcare in many CIS countries, with governments investing in new hospitals and clinics, as well as in training healthcare professionals.Overall, the CIS oncology drugs market is a rapidly evolving and dynamic market, with significant opportunities for growth and innovation. While there are certainly challenges to be overcome, the region's growing focus on healthcare and the increasing availability of innovative treatments suggest that the market will continue to grow in the years ahead.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
